Company news

Argenica Therapeutics Ltd news in 2023

Argenica Therapeutics Ltd's news releases, calls and decks from 2023, newest first.

View company

Appointment of Non-Executive Chair

November 29, 2023

FDA Grants Orphan Drug Designation for ARG-007 HIE Treatment

November 15, 2023

Argenica Receives $2.09m R&D Tax Incentive Cash Rebate

November 12, 2023

ARG-007 Inhibits Cause of Alzheimer's in Pre-Clinical Study

November 2, 2023

Preclinical HIE Study - ARG007 Effective Stand-Alone Therapy

October 17, 2023

Ethics Approval Received for Phase 2 Trial

September 11, 2023

Grant Awarded To Develop Additional Administration Route

September 11, 2023

Positive FDA Feedback Following Pre-Ind Meeting

August 22, 2023

Appendix 4E & Annual Report 30 June 2023

August 22, 2023

Response to ASX Aware Query

August 18, 2023

ARG-007 Prevents Uptake & Aggregation of Key Protein

July 31, 2023

Investor Presentation

July 24, 2023

ARG-007 Phase 2 Clinical Trial Update

July 18, 2023

ARG-007 Protects Brain Cells in Moderate TBI Model

June 21, 2023

Argenica Successfully Completes $4.0m Placement

June 1, 2023

Final Phase1 Clinical Trial Report

May 14, 2023

Latest Preclinical HIE Study Results

April 19, 2023

Significant Non-Dilutive Funding For Preclinical HIE Studies

March 29, 2023

Interim Phase 1 Safety Report Confirms Safety of ARG-007

March 5, 2023

Non-Dilutive Funding Received to Progress Alzheimers Studies

February 21, 2023

Preclinical Data Shows ARG007 Inhibits a Cause of Alzheimers

February 8, 2023

Argenica Awarded $1.2m CRC-P Grant for TBI Project

January 19, 2023

Decks in 2023